Shanghai Ark Biopharmaceutical Co., Ltd announced today that China’s National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for AK0406 injection, the company’s first antiviral drug-Fc …
Harbour BioMed, a global biopharmaceutical company focused on advancing innovative antibody-based therapies in immunology and immune-oncology, has announced the online publication of results from the first-in-human Phase I clinical trial …
